Sugi Predict

Sugi Predict / Targets / COASY

COASY

Bifunctional coenzyme A synthase · Q13057 · COASY on Sugi Atlas →

85 patent compounds predicted against COASY, 30 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15111646 SCHEMBL15111646 0.52 1/20
SCHEMBL5695248 SCHEMBL5695248 0.51 1/20
SCHEMBL15111493 SCHEMBL15111493 0.51 1/20
SCHEMBL15111517 SCHEMBL15111517 0.51 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL5695181) 0.50 1/20
SCHEMBL7208967 SCHEMBL7208967 0.50 1/20
SCHEMBL9305483 SCHEMBL9305483 0.47 1/20
SCHEMBL7689730 SCHEMBL7689730 0.46 1/20
SCHEMBL7208992 SCHEMBL7208992 0.44 1/20
SCHEMBL3884588 SCHEMBL3884588 0.43 1/20
SCHEMBL16324388 SCHEMBL16324388 0.43 1/20
SCHEMBL16324389 SCHEMBL16324389 0.43 1/20
SCHEMBL22261197 SCHEMBL22261197 0.42 1/20
SCHEMBL4314003 SCHEMBL4314003 0.42 1/20
SCHEMBL9533100 SCHEMBL9533100 0.42 1/20
SCHEMBL10087187 SCHEMBL10087187 0.42 1/20
SCHEMBL13950521 SCHEMBL13950521 0.42 1/20
SCHEMBL16322048 SCHEMBL16322048 0.41 1/20
SCHEMBL16322050 SCHEMBL16322050 0.41 1/20
Bromide Bromide (SCHEMBL11628987) 0.41 1/20

Clinical trials — most relevant to COASY by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia PHASE3COMPLETED
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia. PHASE3COMPLETED
Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy. PHASE3COMPLETED
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease PHASE3RECRUITING
Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia PHASE3COMPLETED
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia PHASE3COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia PHASE2COMPLETED
The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels PHASE2COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma PHASE1/PHASE2RECRUITING
Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate PHASE2WITHDRAWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis EARLY_PHASE1COMPLETED
11C-Acetate PET/CT Non-FDG-Avid Tumors nanUNKNOWN
The Safety and Efficacy Study of RiaGev in Healthy Adults nanUNKNOWN
Lifestyle Intervention in Preparation for Pregnancy (LIPP) nanCOMPLETED
Presence of Cyclopropane Fatty Acids (CPFA) in Human Plasma nanCOMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia nanRECRUITING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Natural History Study of FDXR Mutation-related Mitochondriopathy nanCOMPLETED
Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients nanCOMPLETED
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders nanCOMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a COASY binder may also engage these)

ProteinNameSimilarity
Q9DBL7 — 1.000 Q9DBL7 →
Q8MIR4 — 1.000 Q8MIR4 →
Q80UN9 — 0.985 Q80UN9 →
Q91YL3 — 0.984 Q91YL3 →
Q9H3H1 — 0.984 Q9H3H1 →
Q922E4 — 0.983 Q922E4 →
Q9NWZ5 — 0.982 Q9NWZ5 →
NAT10 RNA cytidine acetyltransferase 0.982 landscape →
A0A4X1T4U3 — 0.982 A0A4X1T4U3 →
Q9GZT8 — 0.981 Q9GZT8 →
Q4I2W2 — 0.981 Q4I2W2 →
O88637 — 0.981 O88637 →
Q99447 — 0.981 Q99447 →
Q68EH8 — 0.981 Q68EH8 →
Q5RCH4 — 0.981 Q5RCH4 →
Q8HY87 — 0.980 Q8HY87 →
Q8R123 — 0.980 Q8R123 →
Q58H57 — 0.979 Q58H57 →
Q2T9L8 — 0.979 Q2T9L8 →
Q9BZQ4 — 0.979 Q9BZQ4 →
Q15031 — 0.979 Q15031 →
A2RV18 — 0.979 A2RV18 →
Q5T6J7 — 0.979 Q5T6J7 →
Q5RBL5 — 0.979 Q5RBL5 →
Q4U3U3 — 0.979 Q4U3U3 →
Q95K79 — 0.978 Q95K79 →
Q8K370 — 0.978 Q8K370 →
Q9UDR5 — 0.978 Q9UDR5 →
P00927 — 0.978 P00927 →
Q7RZA2 — 0.978 Q7RZA2 →